Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 28 | 2025 | 373 | 5.100 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 10 | 2022 | 41 | 1.720 |
Why?
|
| Immunosuppressive Agents | 16 | 2025 | 650 | 1.030 |
Why?
|
| Meningoencephalitis | 1 | 2021 | 20 | 0.700 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 18 | 0.700 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 19 | 0.700 |
Why?
|
| JC Virus | 1 | 2021 | 26 | 0.690 |
Why?
|
| Cross Infection | 1 | 2024 | 332 | 0.680 |
Why?
|
| Interferon-beta | 6 | 2011 | 54 | 0.630 |
Why?
|
| Glioblastoma | 1 | 2021 | 331 | 0.530 |
Why?
|
| Ganglioglioma | 1 | 2016 | 20 | 0.500 |
Why?
|
| Recurrence | 6 | 2025 | 1399 | 0.460 |
Why?
|
| Fingolimod Hydrochloride | 4 | 2023 | 33 | 0.440 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2025 | 35 | 0.440 |
Why?
|
| Glatiramer Acetate | 5 | 2025 | 15 | 0.370 |
Why?
|
| Brain Diseases | 2 | 2019 | 283 | 0.370 |
Why?
|
| Osteopontin | 1 | 2010 | 51 | 0.330 |
Why?
|
| Interleukin-17 | 1 | 2010 | 124 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2021 | 1164 | 0.310 |
Why?
|
| Young Adult | 10 | 2025 | 9617 | 0.310 |
Why?
|
| Adult | 27 | 2025 | 30253 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3680 | 0.300 |
Why?
|
| Injections, Epidural | 1 | 2008 | 4 | 0.300 |
Why?
|
| Pneumocephalus | 1 | 2008 | 3 | 0.300 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 14 | 0.300 |
Why?
|
| Dura Mater | 1 | 2008 | 23 | 0.290 |
Why?
|
| Sarcoidosis | 1 | 2008 | 50 | 0.280 |
Why?
|
| Headache | 1 | 2008 | 104 | 0.280 |
Why?
|
| Dimethyl Fumarate | 3 | 2023 | 8 | 0.270 |
Why?
|
| Humans | 44 | 2025 | 126057 | 0.260 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1223 | 0.260 |
Why?
|
| Middle Aged | 20 | 2025 | 27321 | 0.260 |
Why?
|
| Immunologic Factors | 4 | 2024 | 182 | 0.230 |
Why?
|
| Female | 27 | 2025 | 67899 | 0.210 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 114 | 0.210 |
Why?
|
| Adolescent | 14 | 2025 | 19936 | 0.210 |
Why?
|
| Male | 24 | 2025 | 62073 | 0.200 |
Why?
|
| Intracranial Hypertension | 1 | 2025 | 129 | 0.200 |
Why?
|
| Brain | 6 | 2021 | 3032 | 0.190 |
Why?
|
| Immunotherapy | 2 | 2024 | 741 | 0.190 |
Why?
|
| Methotrexate | 3 | 2009 | 313 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2020 | 283 | 0.190 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.180 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 18 | 0.180 |
Why?
|
| Herpes Simplex | 1 | 2022 | 55 | 0.180 |
Why?
|
| Alemtuzumab | 2 | 2020 | 87 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 3 | 2009 | 380 | 0.170 |
Why?
|
| Retrospective Studies | 12 | 2025 | 16768 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2024 | 383 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6550 | 0.160 |
Why?
|
| Methylprednisolone | 3 | 2009 | 93 | 0.160 |
Why?
|
| Health Expenditures | 2 | 2020 | 132 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 51 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 123 | 0.150 |
Why?
|
| Autoantibodies | 3 | 2025 | 423 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 529 | 0.140 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 625 | 0.130 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 99 | 0.120 |
Why?
|
| Aged | 7 | 2025 | 19994 | 0.120 |
Why?
|
| Spinal Cord | 4 | 2021 | 244 | 0.120 |
Why?
|
| Dendritic Cells | 2 | 2011 | 435 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2021 | 12315 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 987 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1421 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2025 | 14330 | 0.100 |
Why?
|
| Quality of Life | 1 | 2022 | 2023 | 0.090 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2011 | 648 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2009 | 286 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2016 | 820 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2011 | 672 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8357 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 52 | 0.090 |
Why?
|
| Child | 4 | 2025 | 25061 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1099 | 0.080 |
Why?
|
| United States | 5 | 2025 | 11200 | 0.080 |
Why?
|
| Infant | 2 | 2024 | 12762 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 222 | 0.080 |
Why?
|
| Linear Models | 2 | 2022 | 672 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 826 | 0.080 |
Why?
|
| Atrophy | 3 | 2021 | 236 | 0.070 |
Why?
|
| Bupivacaine | 1 | 2008 | 29 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5050 | 0.070 |
Why?
|
| Low Back Pain | 1 | 2008 | 39 | 0.070 |
Why?
|
| Transplantation, Autologous | 3 | 2017 | 264 | 0.070 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 32 | 0.070 |
Why?
|
| Prednisone | 1 | 2008 | 239 | 0.070 |
Why?
|
| Biopsy | 2 | 2008 | 1233 | 0.070 |
Why?
|
| Steroids | 1 | 2008 | 157 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 56 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 21 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 110 | 0.070 |
Why?
|
| Roseolovirus Infections | 1 | 2007 | 30 | 0.060 |
Why?
|
| Interferon beta-1a | 4 | 2009 | 21 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2017 | 188 | 0.060 |
Why?
|
| Herpesvirus 6, Human | 1 | 2007 | 54 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 175 | 0.060 |
Why?
|
| Logistic Models | 2 | 2022 | 1744 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1046 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 25 | 0.060 |
Why?
|
| Financing, Personal | 1 | 2004 | 14 | 0.060 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2004 | 20 | 0.060 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 7 | 0.050 |
Why?
|
| Optic Neuritis | 1 | 2025 | 33 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2005 | 158 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 899 | 0.050 |
Why?
|
| Crotonates | 1 | 2023 | 4 | 0.050 |
Why?
|
| Toluidines | 1 | 2023 | 4 | 0.050 |
Why?
|
| Hydroxybutyrates | 1 | 2023 | 30 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 104 | 0.050 |
Why?
|
| Epitopes | 1 | 2005 | 418 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 219 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1845 | 0.050 |
Why?
|
| Nitriles | 1 | 2023 | 149 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 331 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 599 | 0.050 |
Why?
|
| Peptides | 2 | 2004 | 828 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 226 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2002 | 107 | 0.050 |
Why?
|
| Medicare | 1 | 2025 | 418 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 4920 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3649 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2026 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 112 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1294 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 120 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1095 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 56 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 403 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2023 | 330 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 78 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 94 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 82 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 279 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 666 | 0.040 |
Why?
|
| Lactation | 1 | 2020 | 194 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2578 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 148 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1188 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 1708 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2011 | 2898 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 216 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1763 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 220 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1187 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3460 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 540 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 1135 | 0.030 |
Why?
|
| Patient Selection | 2 | 2009 | 702 | 0.030 |
Why?
|
| Disease Progression | 2 | 2015 | 2099 | 0.030 |
Why?
|
| Risk Factors | 2 | 2024 | 10393 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 742 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 777 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1615 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3905 | 0.020 |
Why?
|
| Clonal Anergy | 1 | 2011 | 5 | 0.020 |
Why?
|
| Natalizumab | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2004 | 638 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 63 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1838 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1225 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1216 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 20 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 112 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7404 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 331 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 339 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 449 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 763 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 639 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 304 | 0.010 |
Why?
|
| Chad | 1 | 2004 | 1 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 373 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 131 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 31 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 50 | 0.010 |
Why?
|
| Income | 1 | 2004 | 127 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 116 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 99 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3704 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 332 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 294 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1486 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2027 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 337 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 367 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 180 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 719 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4489 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 518 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1002 | 0.010 |
Why?
|
| Poverty | 1 | 2004 | 429 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 334 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1294 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 458 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1849 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 33105 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 1312 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 17574 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6007 | 0.010 |
Why?
|